SCHEMBL7849070

SCHEMBL7849070

COc1ccc(C(C)(C)C)cc1OC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
PDE4B Q07343 3/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
METAP2 P50579 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16606235 0.90 CA1 (0.46) KMT2AMEN1HTTCA1CA2
SCHEMBL29436012 0.84 CA2 (0.50) KMT2AMEN1CA1CA2CA9
SCHEMBL179467 0.84 CA2 (0.50) KMT2AMEN1CA1CA2CA9
SCHEMBL17708148 0.84 PDE4A (0.43) KMT2AMEN1HTTCA1CA2
SCHEMBL12781659 0.82 CA1 (0.40) KMT2AMEN1HTTCA1CA2
SCHEMBL12781664 0.82 CA1 (0.40) KMT2AMEN1HTTCA1CA2
SCHEMBL12293548 0.81 ALDH1A1 (0.53) KMT2AMEN1CA1CA2CA9
SCHEMBL12313577 0.81 KDM4E (0.49) CA1CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL13019327 0.79 CA1 (0.40) KMT2AMEN1HTTCA1CA2
SCHEMBL26778142 0.79 CA1 (0.40) KMT2AMEN1HTTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 US disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KMT2A 1554/4885MEN1 4265/4885HTT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.